Elimusertib (BAY-1895344) 是一种有效、可口服、选择性的
ATR抑制剂,
IC50值为 7 nM,具有抗肿瘤活性。Elimusertib 可用于实体瘤和淋巴瘤的研究。
生物活性 |
Elimusertib (BAY-1895344) is a potent, orally active and selectiveATRinhibitor with anIC50of 7 nM. Elimusertib has anti-tumor activity[1][2]. Elimusertib can be used for the research of solid tumors and lymphomas[3].
|
IC50& Target |
|
体外研究 (In Vitro) |
Elimusertib potently inhibits the proliferation of a broad spectrum of human tumor cell lines with a median IC50of 78 nM[1]. Elimusertib potently suppresses hydroxyurea-induced H2AX phosphorylation (IC50: 36 nM)[1]. Elimusertib shows good selectivity against mTOR (ratio of IC50values: mTOR/ATR 61)[3]. Elimusertib reveals high selectivity against other related kinases, such as DNA-PK (IC50: 332 nM), ATM (IC50: 1420 nM), and PI3K (IC50: 3270 nM)[3]. Elimusertib has potent antiproliferative activity against various cancer cell lines in vitro, 25 for example in the CRC cell lines HT-29 (IC50: 160 nM) and LoVo (IC50: 71 nM), and in the B-cell lymphoma cell line SU-DHL-8 (IC50: 9 nM)[3].
|
体内研究 (In Vivo) |
Elimusertib shows potent anti-tumor efficacy in monotherapy in a variety of xenograft models of ovarian and colorectal cancer, and causes complete tumor remission in mantle cell lymphoma models[2]. Elimusertib (50 mg/kg; p.o.; b.i.d.; 3 days on/4 days off; for 11 days) exhibits strong antitumor efficacy in the ATM-mutated SU-DHL-8 (ATM K1964E) human GCB-DLBCL cell line derived xenograft model in mice[3]. Elimusertib (20 mg/kg, and 10 mg/kg from day 14; p.o.; daily; 2 days on/5 days off; for 42 days) in combination with Carboplatin (40 mg/kg; i.p.; daily; 1 day on/6 days off) results in synergistic antitumor activity in the platinum-resistant ATM protein low expressing CR5038 human CRC PDX model in NOD/SCID mice[3]. Elimusertib exhibits moderate oral bioavailability (rat 87%, dog 51%) following oral administration (rat and dog 0.6-1 mg/kg)[3]. Elimusertib exhibits terminal elimination half-lives (mouse 0.17 h, rat 1.3 and, dog 1.0 h) due to plasma clearance (3.5, 1.2, and 0.79 L/h/kg respectively) following intravenous administration (mouse, rat and dog 0.3-0.5 mg/kg)[3].
Animal Model: |
Female C.B-17 SCID mice, SU-DHL-8 GCB-DLBCL xenograft model[3] |
Dosage: |
50 mg/kg |
Administration: |
Oral administration, b.i.d., 3 days on/4 days off, for 11 days |
Result: |
Inhibited tumor area. |
Animal Model: |
Male Wistar rats[3] |
Dosage: |
0.3-0.5 mg/kg for i.v.; 0.6-1 mg/kg for oral (Pharmacokinetic Analysis) |
Administration: |
Intravenous injection and oral administration |
Result: |
Oral bioavailability (87%), T1/2(1.3 h). |
Animal Model: |
Female beagle dogs[3] |
Dosage: |
0.3-0.5 mg/kg for i.v.; 0.6-1 mg/kg for oral (Pharmacokinetic Analysis) |
Administration: |
Intravenous injection and oral administration |
Result: |
Oral bioavailability (51%), T1/2(1.0 h). |
|
Clinical Trial |
|
分子量 |
|
性状 |
|
Formula |
|
CAS 号 |
|
运输条件 |
Room temperature in continental US; may vary elsewhere.
|
储存方式 |
Powder |
-20°C |
3 years |
|
4°C |
2 years |
In solvent |
-80°C |
6 months |
|
-20°C |
1 month |
|
溶解性数据 |
In Vitro:
DMSO : 5.4 mg/mL(14.38 mM;Need ultrasonic)
配制储备液
1 mM |
2.6636 mL |
13.3181 mL |
26.6361 mL |
5 mM |
0.5327 mL |
2.6636 mL |
5.3272 mL |
10 mM |
0.2664 mL |
1.3318 mL |
2.6636 mL |
*
请根据半岛bd体育手机客户端 在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的半岛bd体育手机客户端 失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。
In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
-
1.
请依序添加每种溶剂: 0.5%CMC-Na/saline water
Solubility: 4 mg/mL (10.65 mM); Suspended solution; Need ultrasonic and adjust pH to 3 with HCl
-
2.
请依序添加每种溶剂: 10% DMSO90% (20%SBE-β-CDin saline)
Solubility: 1.09 mg/mL (2.90 mM); Suspended solution; Need ultrasonic
此方案可获得 1.09 mg/mL (2.90 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例,取 100 μL 10.9 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。
-
3.
请依序添加每种溶剂: 10% DMSO40%PEG3005%Tween-8045% saline
Solubility: 0.89 mg/mL (2.37 mM); Suspended solution; Need ultrasonic
此方案可获得 0.89 mg/mL (2.37 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例,取 100 μL 8.9 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。
*
以上所有助溶剂都可在本网站选购。
|